SARS-CoV-2感染或COVID-19疫苗接种后起病的炎症性风湿病:COVID-19与ASD组267例报告
多中心观察性研究连续纳入12个月内起病的炎症性风湿病(IRD)267例,其中感染后122例(45.2%)、疫苗后145例(54.8%);感染后队列炎症性关节病比例更高(52.5% vs 37.2%,p=0.013),疫苗后队列风湿性多肌痛比例更高(33.1% vs 21.3%,p=0.032);一线治疗反应良好,但因果关系无法确定。
要点
- 感染后队列炎症性关节病比例高于疫苗后队列(52.5% vs 37.2%,p=0.013)。
- 疫苗后队列风湿性多肌痛比例高于感染后队列(33.1% vs 21.3%,p=0.032)。
- 炎症性关节病与风湿性多肌痛患者一线治疗反应良好,疾病活动度评分分别下降约30%和约70%。
核心结论
- 本文报告了迄今最大队列的SARS-CoV-2感染或COVID-19疫苗接种后新发IRD,虽然因果关系无法确定,但可能临床表现谱广泛,包括炎症性关节病、风湿性多肌痛、结缔组织病和血管炎。
研究设计与样本
- 多中心观察性研究,连续招募12个月期间遇到的IRD病例,纳入标准为风湿表现起病距SARS-CoV-2感染4周内或距COVID-19疫苗接种4周内。
主要发现
- 最终分析队列267例,感染后队列122例(45.2%),疫苗后队列145例(54.8%)。
- 感染后队列炎症性关节病比例高于疫苗后队列(52.5% vs 37.2%,p=0.013)。
- 疫苗后队列风湿性多肌痛比例高于感染后队列(33.1% vs 21.3%,p=0.032)。
- 两队列结缔组织病比例无显著差异(19.7% vs 20.7%,p=0.837),血管炎比例无显著差异(6.6% vs 9.0%,p=0.467)。
- 尽管随访期短,炎症性关节病和风湿性多肌痛患者对一线治疗反应良好,两组基线疾病活动度评分分别下降约30%和约70%。
局限性
- 随访期短。
- 因果关系无法确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To better define the spectrum of new-onset post-COVID-19 and post-COVID-19 vaccine inflammatory rheumatic diseases (IRD) from a large multicentric observational study. METHODS: Consecutive cases of IRD encountered during a 12-month period and satisfying one of the following inclusion criteria: (a) onset of the rheumatic manifestations within 4 weeks from SARS-CoV-2 infection or (b) onset of the rheumatic manifestations within 4 weeks from the administration of one of the COVID-19 vaccines ws recruited. RESULTS: The final analysis cohort comprised 267 patients, of which 122 (45.2%) in the post-COVID-19 and 145 (54.8%) in the postvaccine cohort. Distribution of IRD categories differed between the two cohorts: the post-COVID-19 cohort had a higher percentage of patients classified as having inflammatory joint diseases (IJD, 52.5% vs 37.2%, p=0.013) while the post-vaccine cohort had a higher prevalence of patients classified as polymyalgia rheumatica (PMR, 33.1% vs 21.3%, p=0.032). No differences were detected in the percentage of patients diagnosed with connective tissue diseases (CTD 19.7% vs 20.7%, p=0.837) or vasculitis (6.6% vs 9.0%, p=0.467). Despite the short follow-up period, IJD and PMR patients' response to first-line therapy was favourable, with both groups achieving a drop in baseline disease activity scores of ~30% and ~70% respectively. CONCLUSION: Our article reports the largest cohort published to date of new-onset IRD following SARS-CoV-2 infection or COVID-19 vaccines. Although causality cannot be ascertained, the spectrum of possible clinical manifestations is broad and includes IJD, PMR, CTD and vasculitis.
引用
- Ursini F, Ruscitti P, Addimanda O, et al. Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group. RMD Open. 2023. PMID: 37328292. doi:10.1136/rmdopen-2023-003022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。